##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 7 (2025)

Effectiveness and safety of first-line empirical Helicobacter pylori eradication regimens in Switzerland: an interim analysis from a prospective multicentre registry (Hp-EuReg)

Cite this as:
Swiss Med Wkly. 2025;155:4191
Published
14.07.2025

Summary

BACKGROUND: Helicobacter pylori infection remains prevalent globally. Despite the relatively low reported prevalence in Switzerland, the actual burden is thought to be higher, primarily due to migration. To date, limited evidence is available regarding the effectiveness of Helicobacter pylori eradication therapy in Switzerland.

METHODS: This is a sub-study of the European Registry on Helicobacter pylori Management (Hp-EuReg), an international, multicentre, prospective, non-interventional registry of the routine clinical practice of gastroenterologists. All adult patients with Helicobacter pylori infections were systematically registered in the AEG-REDCap electronic case report form from 2013 to December 2023. Swiss data were analysed for effectiveness on a modified intention-to-treat (mITT) basis, assessing both the therapy duration and the acid inhibition administered with treatment.

RESULTS: A total of 486 adult patients diagnosed with Helicobacter pylori infection were evaluated. Of these, 428 (88%) were treatment-naïve patients. A total of 283 patients with available follow-up were evaluated for effectiveness, adverse events, and compliance. Two first-line regimens accounted for over 90% of cases: amoxicillin-clarithromycin triple therapy in 49% and 10-day single-capsule bismuth quadruple therapy (containing metronidazole-tetracycline-bismuth) in 42%. The overall modified intention-to-treat effectiveness was 92%, achieving 91% in the low-dose proton pump inhibitor (PPI) group (20 mg omeprazole equivalent twice daily) and 96% in the group receiving high-dose (80 mg omeprazole equivalent twice daily) proton pump inhibitors. The lowest effectiveness (82%, 28/34 cases) was reported with 7-day amoxicillin-clarithromycin triple therapy, while the highest effectiveness (97%, 100/103 cases) was achieved with single-capsule bismuth quadruple therapy. Regarding safety, the overall incidence of at least one adverse event was 8.5%, and no serious adverse events were reported.

CONCLUSIONS: In Switzerland, 10-day single-capsule bismuth quadruple therapy with metronidazole, tetracycline, and bismuth demonstrated high eradication success (>90%) and represents a promising empirical first-line treatment option in routine clinical practice.

References

  1. Doulberis M, Pierre NT, Manzini G, Papaefthymiou A, Kountouras J, Klukowska-Rötzler J, et al. Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients. Microorganisms. 2021 Jun;9(7):1361. doi: https://doi.org/10.3390/microorganisms9071361
  2. Rupp S, Papaefthymiou A, Chatzimichael E, Polyzos SA, Spreitzer S, Doulberis M, et al. Diagnostic approach to Helicobacter pylori-related gastric oncogenesis. Ann Gastroenterol. 2022;35(4):333–44. doi: https://doi.org/10.20524/aog.2022.0725
  3. Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023 Jun;8(6):553–64. doi: https://doi.org/10.1016/S2468-1253(23)00070-5
  4. Doulberis M, Kotronis G, Thomann R, Polyzos SA, Boziki M, Gialamprinou D, et al. Review: Impact of Helicobacter pylori on Alzheimer’s disease: What do we know so far? Helicobacter. 2018 Feb;23(1):e12454. doi: https://doi.org/10.1111/hel.12454
  5. Doulberis M, Kountouras J, Rogler G. Reconsidering the “protective” hypothesis of Helicobacter pylori infection in eosinophilic esophagitis. Ann N Y Acad Sci. 2020 Dec;1481(1):59–71. doi: https://doi.org/10.1111/nyas.14449
  6. Hellström PM. Spotlight on gastroenterology - the Nobel Prize Laureates in Physiology or Medicine 2005: John Robin Warren and Barry James Marshall. Scand J Gastroenterol. 2005 Dec;40(12):1383–5. doi: https://doi.org/10.1080/00365520500390402
  7. Jonaitis P, Kupcinskas J, Nyssen OP, Puig I, Gisbert JP, Jonaitis L. Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013-2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Medicina (Kaunas). 2021 Jun;57(7):642. doi: https://doi.org/10.3390/medicina57070642
  8. Nellums LB, Thompson H, Holmes A, Castro-Sánchez E, Otter JA, Norredam M, et al. Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis. Lancet Infect Dis. 2018 Jul;18(7):796–811. doi: https://doi.org/10.1016/S1473-3099(18)30219-6
  9. Piso RJ, Käch R, Pop R, Zillig D, Schibli U, Bassetti S, et al. A Cross-Sectional Study of Colonization Rates with Methicillin-Resistant Staphylococcus aureus (MRSA) and Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenemase-Producing Enterobacteriaceae in Four Swiss Refugee Centres. PLoS One. 2017 Jan;12(1):e0170251. doi: https://doi.org/10.1371/journal.pone.0170251
  10. Boltin D, Beniashvili Z, Lahat A, Hirsch J, Nyssen OP, Mégraud F, et al. European Registry on Helicobacter pylori management (Hp-EuReg): first-line Therapy in Israel. Isr Med Assoc J. 2021 Jan;23(1):38–42.
  11. Caldas M, Pérez-Aisa Á, Castro-Fernández M, Bujanda L, Lucendo AJ, Rodrigo L, et al.; Hp-EuReg Investigators. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics (Basel). 2020 Dec;10(1):13. doi: https://doi.org/10.3390/antibiotics10010013
  12. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8:gutjnl-2022-327745. doi: https://doi.org/10.1136/gutjnl-2022-327745
  13. Nyssen OP, Moreira L, García-Morales N, Cano-Català A, Puig I, Mégraud F, et al. European Registry on Helicobacter pylori Management (Hp-EuReg): most relevant results for clinical practice. Front Gastroenterol (Lausanne). 2022;1:965982. doi: https://doi.org/10.3389/fgstr.2022.965982
  14. McNicholl AG, O’Morain CA, Megraud F, Gisbert JP; As Scientific Committee of the Hp-Eureg on Behalf of the National Coordinators. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter. 2019 Oct;24(5):e12630. doi: https://doi.org/10.1111/hel.12630
  15. Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, et al.; Hp-EuReg Investigators. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021 Jan;70(1):40–54. doi: https://doi.org/10.1136/gutjnl-2020-321372
  16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct;370(9596):1453–7. doi: https://doi.org/10.1016/S0140-6736(07)61602-X
  17. Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019 Feb;24(1):e12554. doi: https://doi.org/10.1111/hel.12554
  18. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009 Jan;65(1):19–31. doi: https://doi.org/10.1007/s00228-008-0576-5
  19. Gatta L, Nyssen OP, Fiorini G, Saracino IM, Pavoni M, Romano M, et al. Effectiveness of first and second-line empirical treatment in Italy: results of the European registry on Helicobacter pylori management. United European Gastroenterol J. 2023 Feb;11(1):103–13. doi: https://doi.org/10.1002/ueg2.12348
  20. Braendli T, Schindler V, Braun DL, Murray FR, Hente JM, Pohl D. Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland. Swiss Med Wkly. 2023 Jan;153(1):40024. doi: https://doi.org/10.57187/smw.2023.40024
  21. Sholeh M, Khoshnood S, Azimi T, Mohamadi J, Kaviar VH, Hashemian M, et al. The prevalence of clarithromycin-resistant Helicobacter pylori isolates: a systematic review and meta-analysis. PeerJ. 2023 Mar;11:e15121. doi: https://doi.org/10.7717/peerj.15121
  22. Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, et al.; European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021 Oct;70(10):1815–22. doi: https://doi.org/10.1136/gutjnl-2021-324032
  23. Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, et al.; Hp-EuReg Investigators. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol. 2021 Jun;116(6):1220–9. doi: https://doi.org/10.14309/ajg.0000000000001246